Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female|Locally Advanced Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: DRUG: Abemaciclib, durvalumab and aromatase inhibitor
Sponsor: Alison Stopeck
Collaborators: Eli Lilly and Company|AstraZeneca